Docetaxel

Biliary Tract Neoplasm

ARCAGY/ GINECO GROUPSmall moleculePhase 2Dormant

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

10 Active assets in the Biliary Tract Neoplasm cohort.

Asset / Sponsor	Phase	Rating
Immunoglobulin G2, Anti-(Human Ctla-4 (Antigen)) (Human Monoclonal Cp-675206 Clone 11.2.1 Heavy Chain) Disulphide With Human Monoclonal Cp-675206 Clone 11.2.1 Light Chain, Dimer National Cancer Institute (NCI)	Phase 2	BB
Durvalumab National Cancer Institute (NCI)	Phase 2	BB
Fulvestrant Seagen, a wholly owned subsidiary of Pfizer	Phase 2	CCC
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Haihua Yuan	Phase 2	CCC
Tucatinib Seagen, a wholly owned subsidiary of Pfizer	Phase 2	CCC